TITLE

Other trials

PUB. DATE
July 2005
SOURCE
Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p18
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Provides information related to recent clinical trials in the U.S. Initiation of trials for a tuberculosis drug from the Global Alliance for TB Drug Development; Benefit of endovascular aneurysm repair for low-risk patients; Recommendation by the Food and Drug Administration for Merck & Co. Inc. to provide safety and efficacy data for pain reliever Arcoxia.
ACCESSION #
17590767

 

Related Articles

  • TB Alliance launches combination drug trial, establishes new pathway to TB and MDR-TB treatment.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article provides information on the clinical trial launched by TB Alliance, a non-profit organization, to test a new drug combination in patients who have tuberculosis as well as those with multidrug-resistant tuberculosis.

  • Nektar Therapeutics initiates Phase I acute pain study.  // PharmaWatch: CNS;May2012, Vol. 11 Issue 5, p13 

    The article reports on the initation of Nektar Therapeutics' Phase I clinical study on the pharmacokinetics and safety of NKTR-192, a mu-opioid analgesic candidate. It notes that the study discovers a decline in self-administration of NKTR-192 when it comes to forecasting the abuse liability of...

  • DOV shows positive phase III results for bicifadine.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p14 

    Presents results of a phase III clinical trial of non-narcotic analgesic bicifadine. Indication of bicifadine; Efficacy of bicifadine as an analgesic; Demonstration of the analgesic effects of bicifadine in a well accepted clinical pain procedure.

  • Pain Therapeutics begins enrollment of patients for Oxytrex phase III trial.  // PharmaWatch: CNS;April 2004, Vol. 3 Issue 4, p13 

    Reports on the enrolment of patients for the clinical trial of the oral painkiller, Oxytrex, by Pain Therapeutics Inc. Use of the drug in treating patients who suffer from sever chronic pain; Detection of the ability of the painkiller to inhibit an excitatory effect of opioid receptors; Design...

  • Arthritis patients embracing natural alternative.  // Presbyterians Today;Oct2011, Vol. 101 Issue 8, p15 

    The article offers information on the efficacy of natural product Panitrol, formulated by Enzyme Labs, in reducing or eliminating pain in patients with long term injuries including arthritis, chronic pain, and fibromyalgia. It is inferred that Panitrol, which is a combination of natural herbs,...

  • Pain Relief Faster than Snail's Pace. Luntz, Stephen // Australasian Science;Jul2005, Vol. 26 Issue 6, p8 

    Focuses on clinical trials for ACV1 compound pain relief drug which is derived from a toxin produced by cone shell snails. Advantage of ACV1 over morphine; Benefits of ACV1 to cure post-surgical and neuropathic pain; Tests being conducted to ensure the safety of ACV1.

  • Phase II/III.  // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p16 

    Provides information related to latest phase II/III clinical trials. Initiation of a trial for an inhalable form of treprostinil for pulmonary hypertension by Lung Rx; Efficacy of Fibrillex at improving symptoms of Amylois A Amyloidosis, based on Neurochem Inc.'s trial.

  • Comparative Study on the Bioequivalence of Two Different Gabapentin Formulations: A randomised, two-period, two-sequence, crossover clinical trial in healthy volunteers. Almeida, Susana; Filipe, Augusto; Almeida, Ana; Antonijoan, Rosa; GarcĂ­a-Gea, Consuelo; Gich, Ignasi; Barbanoj, Manuel; Caturla, Maria Cruz // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Feb2006, Vol. 56 Issue 2, p59 

    The bioequivalence of two capsule formulations containing 400 mg gabapentin (CAS 60142-96-3) was assessed in 24 healthy volunteers in an open, randomised, crossover, 2 periods x 2 sequences, with a minimum washout period of 7 days, single-dose study. Plasma samples were obtained at fixed time...

  • Ann Arbor biotech testing osteoporosis drug. Henderson, Tom // Crain's Detroit Business;3/10/2008, Vol. 24 Issue 10, p25 

    The article offers information regarding the drug trials of VEL0230, being conducted by Velcura Therapeutics Inc. It states that Velcura, an Ann Arbor, Michigan-based biotech heavily funded by federal and state grants since it was founded in 2001, has begun clinical trials of a new drug to fight...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics